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Glial activation and subsequent release of neurotoxic proinflammatory factors are believed to play an important role in the
pathogenesis of several neurological disorders including Parkinson’s disease (PD). Inhibition of glial activation and inflammatory
processes may represent a therapeutic target to alleviate neurodegeneration. Securinine, a major natural alkaloid product from
the root of the plant Securinega suffruticosa, has been reported to have potent biological activity and is used in the treatment of
neurological conditions such as amyotrophic lateral sclerosis, poliomyelitis, and multiple sclerosis. In this study, we explored the
underlyingmechanisms of neuroprotection elicited by securinine, particularly its anti-inflammatory effects in glial cells. Our results
demonstrate that securinine significantly and dose-dependently suppressed the nitric oxide production in microglia and astrocytic
cultures. In addition, securinine inhibited the activation of the inflammatory mediator NF-𝜅B, as well as mitogen-activated protein
kinases in lipopolysaccharide- (LPS-) stimulated BV2 cells. Additionally, securinine also inhibited interferon-𝛾- (IFN-𝛾-) induced
nitric oxide levels and iNOS mRNA expression. Furthermore, conditioned media (CM) from securinine pretreated BV2 cells
significantly reducedmesencephalic dopaminergic neurotoxicity comparedwithCM fromLPS stimulatedmicroglia.These findings
suggest that securinine may be a potential candidate for the treatment of neurodegenerative diseases related to neuroinflammation.
1. Introduction
Inflammation of the central nervous system (CNS) is a key
contributing factor in several neurodegenerative diseases.
Glial cells, including microglia and astrocytes, are known
to be the major mediators of neuroinflammation. Activated
microglial cells trigger an inflammatory response that is then
maintained and often times amplified by astrocytes. This, in
turn, exposes neurons to inflammatory mediators that can
cause neuronal cell death [1]. Neurodegenerative CNS dis-
eases including Alzheimer’s disease (AD), Parkinson’s disease
(PD), Huntington’s disease (HD), amyotrophic lateral scle-
rosis (ALS), and age-related macular degeneration (ARMD)
have all been associatedwith chronic neuroinflammation and
activation of both microglia and astrocytes [2]. This chronic
inflammation can lead to the accumulation of neurotoxic
molecules including proinflammatory cytokines, proteinases,
and reactive oxygen species (ROS), which participate in
the neurodegenerative process and can ultimately lead to
neuronal cell death [3–5]. It is hypothesized that inhibiting
microglial-mediated induction of the neuroinflammatory
process may prove to be neuroprotective and therefore
inhibitory compounds targeting this process are likely to have
therapeutic value.
Medicinal plants and their active components are cur-
rently the subject of extensive biomedical research. Many
of these plant-derived medications have been validated by
traditional usage over the centuries, but the specific bioactive
components have not been identified or are not fully char-
acterized. Traditional herbal medicines with neurotrophic
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and neuroprotective properties have been demonstrated to
prevent neurodegeneration and neuroinflammatory diseases
[6]. This suggests that these traditional medicinal herbs
possess neuroprotective benefits through distinct and mul-
tiple mechanisms, including anti-inflammation [7–10]. Nat-
ural compounds specifically targeted to blocking microglial
activation and therefore blocking the initiation of CNS
inflammation may prove to be an effective therapy to prevent
neurodegenerative and neuroinflammatory diseases.
Securinine, a major natural alkaloid product from the
root of the plant Securinega suffruticosa, has been reported
to have potent biological activity and has been used clinically
in several countries [11]. Securinine has been found to be an
antagonist of the 𝛾-amino butyric acid (GABA) A receptor
and as such is currently used in the treatment of neurological
conditions such as ALS, poliomyelitis, and multiple sclerosis
[12–14]. Additionally, securinine has been shown to be a
macrophage agonist, enhancing bacterial clearance via a
mechanism distinct from toll-like receptors (TLRs) [15].
Securinine appears to stimulate p38 MAPK activity through
antagonism of the GABA A receptor in monocytes [16].
Securinine has also been found to stimulate apoptosis in p53-
null colon cancer cells [1, 17]. However, the potential anti-
inflammatory role of securinine on glial activation and the
mechanisms involved have not been thoroughly explored.
In the present study, to determine whether securinine can
suppress glial inflammatory activation and act as a mediator
of neuroinflammation, we tested the effects of securinine on
lipopolysaccharide- (LPS-) induced activation of microglia
and astrocytes. The results demonstrated that securinine
inhibits the activation of the inflammatory mediator NF-
𝜅B, as well as its upstream MAPK activators including
ERK. Further, securinine also silences iNOS expression and
NO production, both of which are activated by NF-𝜅B.
Importantly, we demonstrate that inhibition of LPS-induced
microglial activation with securinine is neuroprotective in
the context of primarymesencephalic dopaminergic neurons
representing an in vitro model of PD.
2. Experimental Procedures
2.1. Cell Culture. The cell culture reagents used in this study
were purchased from Mediatech, Inc. (Manassas, VA, USA).
BV2 microglial cells were cultured in Dulbecco’s modified
Eagle medium (DMEM) containing 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin mixture (10,000 u/mL)
(Sigma Aldrich, St Louis, MO). RAW 264.7 macrophage
cell lines (ATCC, TBI-71) were grown and maintained in
DMEM supplemented with 10% heat inactivated FBS and 1%
Penicillin-streptomycin mixture (10,000 u/mL) at 37∘C, 5%
CO
2
.
Primary mouse astrocytes and microglia were isolated as
described previously [18]. We used postnatal day 2 pups to
generate primary glial cultures. Briefly, cortical tissues from
C57/BL6 mice were dissected out and the tissue was digested
with papain for 30minutes at 37∘Candplated in poly-L-lysine
coated T75 flasks in DMEM supplemented with 10% FBS. For
astrocytes culture isolation, after 1 week of culture, the flasks
were shaken to remove microglia followed by trypsinization
and plating onto poly-L-lysine coated plates or chambered
slides at 1 × 105 cells/well. The cells were only used for a
maximum of three passages; more than 95% of cells stained
positively for the astrocyte marker GFAP in these cultures.
Primary microglial cultures were prepared from the cor-
tex of C57/BL6 mice as described above. Briefly, mixed glial
cells were cultured for 3-4 weeks in DMEM supplemented
with 10% FBS. The astrocyte monolayer was removed by
incubation for 30min with 0.25% trypsin/2.12mM EDTA
(Mediatech, Inc., Manassas, VA) diluted 1 : 4 with DMEM.
The remaining isolated microglial cells were plated into 96-
well plates at a density of 5 × 104 cells/well and 6-well plates
at 5 × 105 cells/well. The purity of microglia cultures was
assessed using microglial marker CD11b or Iba1; 95% of
cells stained positively for these microglial markers; 1–3%
stained positively for GFAPmarker.Themicroglial cells were
cultured for 2 days before drug treatment.
Primary mesencephalic cultures were isolated as previ-
ously described from our laboratory [19]. Briefly, ventral
mesencephalon was dissected from embryonic day 14 of
C57/BL6 mice. The tissue was dissociated mechanically
and then digested enzymatically with papain solution as
per manufactures instructions (Worthington Biochemical,
Lakewood, NJ). After 4 d in vitro, the neuronal cultures were
taken for conditionmedia exposure from activatedmicroglial
cells.
2.2. Cell Viability Assay. Cell viability was determined by
calorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphen-
yltetrazolium bromide) assay as described previously from
our laboratory [20]. BV2 microglial cells were plated into 96-
well culture plates at a density of 1 × 104 cells/mL in 100𝜇L
culture medium per well. The cells were allowed to settle for
24 h before the addition of different concentrations of securi-
nine for 24 h (Sigma Aldrich, USA). After 24 h of treatment,
MTT solution (5mg/mL) was added to each well and plate
was incubated at 37∘C for 2–4 h. The medium was aspirated
and the resulting formazan crystals were dissolved in 200𝜇L
of dimethyl sulfoxide before measuring the absorbance at
570 nm using a spectrophotometer.
2.3. Measurement of Nitrite (NO2−) Levels. The level of
NO2−, a stable downstream product of NO, secreted by
activated glial cells in culture media was measured using
the Griess Reagent assay method as previously described
[21]. The microglia, astrocytes, and macrophages cultures
were exposed to inflammation inducing agents in presence
or absence of different concentration of securinine for 24 h.
Following the treatments, NO levels in the culturemediawere
measured bymixingwith equal volume ofGriess Reagent and
OD was measured at 540 nm on a microplate reader (Molec-
ular Devices, CA). The data are representative of results
obtained from four independent experiments performed in
triplicate (mean ± SD).
2.4. NF𝜅B-Luciferase Activity Assay. BV2 cells stably express-
ing an NF𝜅B-luciferase construct were plated into 96-well
cell culture plates at a density of 10,000 cells/well. The NF𝜅B
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binding reporter plasmid contains three copies of the 𝜅B-
binding sequence fused to the firefly luciferase gene which
was purchased from Clontech (Mountain View, CA, USA).
Cells were preexposed to securinine followed by cotreatment
with LPS for 24 hr treatment. Luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System kit
as per the manufacturer’s instructions (Promega).
2.5. Western Blotting Analysis. Following various treatments,
BV2 cells and astrocytes were collected from Petri dishes
by trypsinization and lysed in cold lysis buffer containing
protease inhibitors as previously described [21]. The whole
cell lysates were sonicated and the protein concentration
was measured using a Bradford protein assay kit (Bio-Rad,
Hercules, CA). Twenty-five to 50 𝜇g of total protein was
subjected to 10% SDS-PAGE and protein was transferred
to a polyvinylidene difluoride membrane. Immunodetection
was carried out by standard procedures using the following
dilutions of antibodies: iNOS (rabbit polyclonal antibody,
1 : 1000), phospho-NFkB (p65) (rabbit polyclonal antibody,
1 : 1000), PARP (rabbit polyclonal antibody, 1 : 1000), the
phospho- or total forms of ERK1/2, p38 MAPK, JNK, and
pSTAT1 (rabbit polyclonal antibodies, 1 : 1000, Cell Signaling
Technology, USA), and beta-actin (mouse monoclonal anti-
body, 1 : 10,000, Sigma Aldrich, USA). Secondary antibodies
were horseradish peroxidase conjugated to either goat anti-
rabbit IgG or anti-mouse IgG (Cell Signaling Technology,
USA). The membranes were developed using an enhanced
chemiluminescence (ECL) detection system (Pierce, USA).
Band intensities were determined using the Image-Pro Plus
6.0 software (Bio-Rad).
2.6. Quantitative Polymerase Chain Reaction (qPCR) Analysis.
BV2 cells and primary astrocytes cultured were challenged
with LPS (BV2, 500 ng/mL; primary astrocytes, 1𝜇g/mL +
IFN-𝛾 40U/mL) in the presence or absence of securinine
(10 𝜇M) for 6 h. Total RNA was isolated from the cells via
TRIzol method and cDNA was synthesized using Promega
GoScript Reverse Transcription System (Madison, WI,
USA). Quantitative PCR was performed using SYBR Green
PCR Master Mix reagent and gene-specific primers. Data
were analyzed by using the comparative threshold cycle (Ct)
method. Altered mRNA expression levels following treat-
ment were calculated following normalization to GAPDH.
The ratios obtained after normalization are expressed as fold
change versus corresponding controls [20].
2.7. Neurotoxicity of BV2 Conditioned Media in Primary Mes-
encephalic Cultures. Primary mesencephalic cultures were
isolated as described above. After 4 days in vitro, dopamin-
ergic neurons were exposed to conditioned media (CM)
from BV2 microglial cells treated with LPS ± securinine.
The CM was prepared as follows: BV2 cells cultured in 6-
well plates were stimulated with LPS (500 ng/mL) in the
presence and absence of securinine (10𝜇M) for 24 h. CM
was collected from all the groups and centrifuged at 2,000 g
for 10min to remove any cell debris. The CM from control,
securinine, and LPS versus LPS + securinine-treated cells
was diluted (1 : 4) in neuronal culture media before adding
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Figure 1: Effects of securinine on the cell viability of the BV2
microglia cell line. BV2 cells were treated with 2.5–20𝜇M of
securinine without LPS treatment or in the presence of 500 ng/mL
LPS treatment for 24 h. Cell viability was measured via the MTT
assay and data was expressed as mean ± SEM for three independent
experiments. ∗∗𝑃 < 0.05, significantly different from the value in
control cells.
to mesencephalic cultures. After 72 h exposure, the cells
were fixed in 4% paraformaldehyde and immunostained with
anti-TH antibody and Alexa Fluor 488 secondary antibody.
Total numbers of TH-positive neurons were counted in 3–5
separate wells for each condition. Experiments were repeated
with cultures isolated from three independent dissections.
2.8. Statistical Analysis. Unless otherwise stated, all experi-
ments were performed in triplicate and repeated at least three
times. The data are presented as mean ± SEM and statistical
comparisons between groups were performed by one-way
ANOVA followed by Student’s 𝑡-test. Multiple comparisons
of data from in vitro experiments were evaluated by two-way
ANOVA followed by Bonferroni post hoc testing. Statistical
significance was set at 𝑃 < 0.05 for all analyses.
3. Results
3.1. Securinine Does Not Elicit Cellular Toxicity in Microglial
BV2 Cells at Concentrations up to 15 𝜇M. To determine
whether securinine displays cytotoxic effects in glial cell
types, we treated BV2 cells, an immortalized murine
microglial cell line, with increasing concentrations of the
compound for 24 h, followed by assessment of cell viabil-
ity using the MTT assay. No significant cytotoxicity was
observed up to 15 𝜇M, whereas 15% toxicity was observed at
20𝜇M (Figure 1).This toxicity may be due to the induction of
apoptosis as previously reported at 30 𝜇M in cancer cell lines
[17]. Based on this data, we chose to use 10 𝜇M securinine
for all subsequent assays. Additionally, the concentration of
LPS (500 ng/mL) used to induce NO production also did not
affect cell viability (data not shown).
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Figure 2: Securinine inhibits LPS-inducedNOproduction in the BV2 cell line and inmouse primarymicroglia challengedwith LPS exposure.
BV2 microglial cells (a) and mouse primary microglia (b) were pretreated with securinine (2, 5, and 10 𝜇M) for 1 h and then stimulated with
LPS (500 ng/mL) for 24 h. NO levels in the medium were determined using the Griess Reagent system.The data are expressed as mean ± SD,
𝑛 = 4. ∗𝑃 < 0.01, significantly different from control samples. ∗∗𝑃 < 0.05 significantly different from the LPS-treated group alone.
3.2. Securinine Inhibits LPS-Induced Inflammatory NO Pro-
duction in Both BV2 Cells and Primary Mouse Microglia. To
examine the potential anti-inflammatory activity of securi-
nine in the context of microglial activation, we initially
studied the effects of securinine on the production of inflam-
matorymediators in BV2 andmouse primarymicroglia, both
challenged with LPS. As part of the inflammatory response,
activated glial cells rapidly induce the expression of inducible
nitric oxide synthase (iNOS), a key enzyme required for
generating nitric oxide (NO), a reactive nitrogen species
(RNS) causing protein and mitochondrial damage leading
to apoptosis [22]. In BV2 cells, LPS markedly induced NO
production as detected by the accumulation of nitrite in the
culture medium after 24 h. In the presence of securinine
however, there was a dose-dependent inhibition of NO
production to almost control levels at the highest drug con-
centration. Securinine alone had no effect on NO production
(Figure 2(a)). Likewise, we observed significant inhibition of
LPS-induced NO production by securinine within primary
microglia cell cultures (Figure 2(b)).
3.3. Securinine Inhibits LPS-Induced Expression of the NO-
Synthesizing Enzyme, iNOS, and Proinflammatory Cytokines.
To examine whether the reduction of NO production by
securinine was due to reducedmRNA and protein expression
of iNOS and also effect of securinine on the expression
of various proinflammatory cytokines, real-time PCR and
Western blot analyses were conducted in LPS-stimulated
BV2 and primary microglial cells. Both primary and BV2
cells were preincubated 1 h with securinine (10𝜇M) and
then stimulated for 6 h with LPS (500 ng/mL). As shown
in Figures 3(A1) and 3(A2), securinine significantly reduced
the expression of proinflammatory molecules such as TNF-
𝛼 and IL-1𝛽 in both BV2 and primary microglial cells, while
the compound alone did not induce any significant changes
in gene expression. Furthermore, as shown by qPCR and
Western blotting (Figures 3(B1) and 3(B2)), securinine dose-
dependently inhibited LPS-induced iNOS expression at the
mRNAandprotein levels in both primary BV2 andmicroglial
cells.
3.4. Securinine Attenuates LPS-Induced NF𝜅B Activation.
LPS and other inflammatory stimuli are known to induce
iNOS expression in glia cells via the activation of the tran-
scription factor NF𝜅B. Therefore, we examined whether the
anti-inflammatory effects of securinine were due to blockade
of NF-𝜅B activation within BV2 cells. NF-𝜅B is normally
activated by phosphorylation of I𝜅B proteins, targeting them
for rapid degradation through the ubiquitin-proteasome
pathway and releasing NF-𝜅B to enter the nucleus where
it regulates gene expression. Western blot analysis demon-
strated LPS-induced phosphorylation of p65 subunit which
was significantly inhibited by pretreatment with securinine
(Figure 4(a)). Furthermore, LPS-induced NF𝜅B-dependent
transcriptional activity was also significantly reduced by
treatment with securinine (10 𝜇M). These data suggest that
securinine can prevent NF𝜅B-mediated induction of inflam-
matory pathways.
3.5. Securinine Reduces LPS-Induced MAPK Phosphorylation.
Inhibitors targeting MAPK signaling pathways have been
known to exhibit anti-inflammatory activity [23]. To deter-
mine whether anti-inflammatory activity of securinine is due
to modulation of MAPKs activity, BV2 cells were pretreated
with securinine (10 𝜇M) for 1 h and then stimulated with LPS
for an additional 1 h incubation period. Based on preliminary
time course studies (data not shown), 1 h treatment of LPS
was determined to be optimal for MAPK phosphorylation.
Western blot analysis was carried out using phosphoantibod-
ies or total antibodies against the three MAPKs, p38 MAPK,
JNK, and ERK1/2. Western blot analysis showed that the
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Figure 3: Securinine represses LPS-induced proinflammatory cytokines and iNOS expression in BV2 and mouse primary microglia. (a)
Securinine inhibits proinflammatory cytokine expression following LPS exposure. BV2 and primary microglial cells were preincubated with
securinine for 1 h before stimulation with LPS (500 ng/mL). After 6 h of stimulation, total RNA was isolated and levels of mRNA expression
of proinflammatory cytokines TNF-𝛼 and IL-1𝛽 analyzed via quantitative real-time PCR ((A1) BV2 cells and (A2) mouse primary microglia).
(b) Securinine represses LPS-induced iNOSmRNA and protein expression in BV2 (B1) and primary microglia cells. After 24 h of stimulation
with LPS (500 ng/mL), the level of iNOS protein was monitored by Western blot analysis ((B1) BV2 cells and (B2) primary microglia cells).
Data are mean ± SD of three different experiments. ∗𝑃 < 0.001 versus control; ∗∗𝑃 < 0.05 versus LPS-treated group alone.
securinine significantly repressed the phosphorylation of p38
MAPK, JNK, and ERK1/2, respectively, but did not affect the
expression levels of ERK1/2, JNK, and p38 MAPK in LPS-
stimulated BV2 microglia (Figure 5).
3.6. Securinine Reduces IFN-𝛾-Induced NO Production, iNOS
mRNA Expression, and STAT1𝛼 Activation. Multiple tran-
scription factors participate in the regulation of iNOS pro-
motor activity. In addition to LPS, IFN-𝛾 is a well-established
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Figure 4: Securinine attenuates LPS-induced activation of NF-𝜅B in BV2 microglia. (a) BV2 microglial cells were treated with securinine for
1 h followed by stimulation with 500 ng/mL LPS. After 30min of LPS stimulation, isolated nuclear lysates were subjected to Western blotting
to assess translocation of phosphor-65 protein to the nucleus. PARP was used as a nuclear loading control. (b) BV2 cells were transiently
transfected with NF-𝜅B-Luc plasmid for 24 h and then treated with 500 ng/mL LPS for 4 h ± securinine. Whole cell lysates were assayed via
the luciferase activity (mean ± SE, 𝑛 = 4); ∗𝑃 < 0.05 versus control. ∗∗𝑃 < 0.05 versus LPS. ∗∗∗𝑃 < 0.05 versus LPS.
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Figure 6: Securinine pretreatment reduces IFN-𝛾-induced NO production, iNOS mRNA expression, and phosphorylation of STAT1𝛼 in
BV2microglia. BV2microglial cells were pretreated with securinine for 1 h and then challenged with IFN-𝛾 (50U/mL) for 24 h (a), 6 h (b), or
30min (c). The expression levels of nitric oxide, iNOS mRNA, and tyrosine phosphorylation of STAT1𝛼 were determined by Griess Reagent
assay (a), real-time PCR analysis (b), orWestern blotting (c), respectively.The data are expressed asmean ± SD, 𝑛 = 4. ∗∗𝑃 < 0.01 significantly
different from control samples. ∗∗∗𝑃 < 0.05, significantly different from the LPS-treated group.
stimulus that promotes the expression of inflammatory
molecules (e.g., iNOS) through STAT1𝛼, but independent
of NF-𝜅B [23]. Thus, the effects of securinine on IFN-𝛾
activation were also investigated. As shown in Figure 6(a),
securinine inhibited IFN-𝛾-induced NO production in a
concentration-dependent manner with maximum inhibition
achieved at 10𝜇M. Securinine also significantly reduced IFN-
𝛾-induced iNOS mRNA expression levels (Figure 6(b)) and
phosphorylation of STAT1𝛼 (Figure 6(c)).
3.7. Securinine Protects Neurons through Inhibition of Micro-
glial Activation. Previous studies from our own laboratory
and others have demonstrated that activatedmicroglia induce
neural cell death and amplify the progression of neuronal
degeneration [20, 24]. Since our data suggested that securi-
nine can suppress microglial activation, we investigated
whether this translated to noncell autonomous neuropro-
tective effects. Conditioned media (CM) from LPS-treated
BV2 cells in the presence or absence of securinine pretreat-
ment were added to primary mesencephalic cultures and
cell viability monitored in the latter via tyrosine hydroxy-
lase (TH) immunocytochemistry and TH-positive neuronal
counting (Figures 7(a) and 7(b)). Results from these studies
demonstrated that CM from LPS-stimulated microglia (LPS-
CM) showed significant toxicity to TH-positive neurons,
presumably as a consequence of toxic factors secreted by the
activatedmicroglia. In addition to cell loss, neuritic processes
were also shortened in surviving TH-positive neurons (Fig-
ure 7(b)). Securinine alone, under normal conditions, did
not influence TH-positive viability. However, pretreatment of
microglial cells with securinine provided significant neuro-
protection against toxicity associated with CM isolated from
the activated microglia (LPS/Scu-CM versus LPS-CM), sug-
gesting that securinine may exert its neuroprotective effects,
at least partly, via reducing the production and secretion of
inflammatory mediators from the microglia (Figure 7(b)).
3.8. Effects of the Securinine on the Inflammatory Activation of
RAW264.7Macrophage Cells and Primary Astrocyte Cultures.
Finally, in order to explore whether securinine can poten-
tially also elicit anti-inflammatory effects in other cell types
beyondmicroglia, we assessed NO production in RAW 264.7
macrophage cells and also in primary astrocyte cultures in the
presence and absence of pretreatment with the compound.
Securinine was found to dose-dependently decrease NO
production in LPS-stimulated RAW264.7 macrophage cells
(Figure 8(a)) and also in primary mouse astrocyte cultures
(Figure 8(b)).When astrocytes were stimulatedwith LPS plus
IFN-𝛾, greater levels of NO production were achieved, which
were similarly inhibited by the securinine (Figure 8(c)).These
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Figure 7: Securinine protects primary mesencephalic dopaminergic neurons through inhibition of BV2 cells activation. BV2 cells were
stimulatedwith LPS (500 ng/mL)± securinine (10 𝜇M) for 24 h. CM from control (BV2-CM), securinine-treated (Sec-CM), LPS-treated (LPS-
CM), and LPS/securinine-treated (5 and 10 𝜇M; LPS + Sec 5𝜇M-CM, LPS + Sec 10𝜇M-CM) BV2 cells was added to primary mesencephalic
cultures. After 72 h, cultures were immunostained for TH+ neurons (a) and the number of TH+ neurons was counted (b). Data are expressed
as mean ± SD, 𝑛 = 4; ∗∗𝑃 < 0.01, compared with control-CM group, ∗𝑃 < 0.05, compared with LPS-CM group.
results indicated that the small molecule securinine also has
anti-inflammatory effects in peripheral macrophages and in
astrocytes.
4. Discussion
In the present study, we examined the anti-inflammatory
properties of the small molecule natural product securinine
in glial populations and in macrophages and have delin-
eated the potential signal transduction pathways involved
in these processes. Our studies demonstrate that securinine
strongly inhibits the inflammatory activation of microglia,
astrocytes, and macrophages. Securinine significantly and
dose-dependently reducedNOproduction in LPS-stimulated
BV2 microglial cells and primary microglia and astrocyte
cultures. NF-𝜅B and MAPK pathways were at least partly
involved in the anti-inflammatory mechanisms of securi-
nine. Furthermore, securinine also inhibited IFN-𝛾-induced
NO production and STAT1𝛼 activation. Finally, conditioned
media from securinine pretreated BV2 microglial cells sig-
nificantly reduced dopaminergic neurotoxicity compared
to LPS-treated group alone. These results suggested that
securinine might have therapeutic potential for various glial-
mediated neuroinflammatory diseases.
Activation of microglial cells, the resident immune
macrophage-like cells in the brain, is beneficial during
acute infection or toxic insult by eliminating “sick” neurons
that are no longer functional. However, in the presence of
ongoing progressive brain damage, they can become chroni-
cally activated, resulting in sustained aberrant inflammatory
response [25]. Glial cell activation and increased production
of proinflammatory products derived from them have been
implicated in the pathophysiology of several neurodegenera-
tive diseases, such as AD, PD, and HD [26]. Recently, much
attention has been paid to therapeutic strategies aimed at
inhibiting neurotoxic microglial activation. Although non-
steroidal anti-inflammatory (NSAIDs) medications demon-
strate neuroprotection in various disease models, such medi-
cations can have serious side effects following their long-term
usage, leading to searches for better alternatives [27]. Recent
studies have demonstrated that natural products and their
components are good alternative candidates for therapeutic
purposes due to their reputation for being safe, inexpensive,
and readily available [28].
Activated microglia secretes proinflammatory mediators
including cytokines such as IL-6 and TNF-𝛼, reactive oxygen
species, and reactive nitrative species such asNO.Nitric oxide
(NO) is a unique biological messenger which mediates sev-
eral physiological functions. However, under conditions of
excessive production, NO appears to be neurotoxic suggest-
ing that NO may play an important role in pathophysiology
of neurodegenerative diseases [29]. In this current study, we
have demonstrated that production of NO by LPS-activated
microglia (both BV2 and primary microglia) is significantly
inhibited in a dose-dependent manner by securinine at both
the mRNA and protein levels.
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Figure 8: Securinine pretreatment inhibits LPS-induced NO production in RAW 264.7 macrophage cells and in primary astrocyte cultures.
RAW 264.7 macrophage cells or primary astrocyte cultures (10 × 104 cells/well in 48-well plates) were incubated with 500 ng/mL of LPS or
LPS/IFN-𝛾 (50 unit/mL) in the presence or absence of securinine (10 𝜇M) for 24 h. The amount of nitrite secreted into the supernatant was
measured using the Griess Reagent assay ((a) RAW 264.7 cells, ∗∗∗𝑃 < 0.05 versus control; (b and c) primary astrocyte cultures). The data
were expressed as the mean ± SD (𝑛 = 3) and are representative of three independent experiments. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, significantly
different from cells treated with LPS only.
We next examined the effects of securinine on LPS-
induced activation of various MAPKs as well as NF-𝜅B-
mediated pathways. It is well established that MAPKs and
NF-𝜅B transcription factors play an important role in reg-
ulation of expression of proinflammatory cytokines and
enzymes including iNOS, TNF-𝛼, IL-1𝛽, IL-6, and COX-2
[30].Therefore, for a compound to exhibit anti-inflammatory
effects this should require an ability to attenuate the activation
of these pathways. The signaling mechanisms involved in
NF-𝜅B activation have been well established and involve a
cascade of cytoplasmic proteins leading ultimately to the
translocation of the p65 subunit of NF-𝜅B into the nucleus
resulting in transcription of downstream proinflammatory
genes [31, 32].
In this study, we show, as expected, phosphorylation of
all three MAPKs following LPS treatment of BV2 microglia
as well as phosphorylation of NF-𝜅B p65 and increased NF-
𝜅B promotor activity. Securinine dose-dependently inhibited
LPS-induced NF-𝜅B phosphorylation and activation as well
as LPS-induced p38, JNK, and ERK phosphorylation in these
cells.
Earlier studies have demonstrated that the expression
of iNOS is regulated coordinately by the action of several
transcription factors such as NF-𝜅B, AP-1, and STAT1 [33].
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Interestingly, our results demonstrate that, in addition to
attenuating NF-𝜅B activation, securinine also inhibited IFN-
𝛾-induced NO production, iNOS mRNA expression, and
STAT1𝛼 activation (Figure 6). These results indicate that
securinine regulates proinflammatory gene expression in
both NF-𝜅B dependent and independent manner.
Recent studies have emphasized the role of peripheral
macrophages infiltration in reactive gliosis following trau-
matic brain injury (TBI) and also in the case of spinal cord
injuries [34]. Furthermore, when the blood-brain barrier is
compromised during neurological disorders such as multiple
sclerosis andAlzheimer’s and Parkinson’s diseases, peripheral
immune cells including monocytes, neutrophils, T cells, and
B cells can enter the brain where they execute distinct
cell-mediated effects [35]. Our studies with macrophages
and astrocytes further demonstrate that securinine not only
inhibits microglial activation but also inhibits peripheral
macrophages and astrocytes indicating the broad anti-
inflammatory action of securinine.
A recent study reported that securinine can reduce
the glial inflammatory responses induced by beta-amyloid
protein, improving both cognitive deficits and neurodegen-
eration in beta AP (25–35)-treated rats [36] Although the
study suggested that securinine was neuroprotective in this
model, the exact mechanisms involved in this process were
not explored. In the present study, cultured media from
LPS/securinine-treated microglia provided almost complete
dopaminergic neuroprotection compared with CM from
LPS-stimulated microglia. Taken in total, our results sug-
gest that securinine offers neuroprotective effects via reduc-
ing abnormal production of proinflammatory mediators.
Although CM experiments utilizing LPS-stimulated BV2
microglia with primary mesencephalic cultures may not
completely mimic the in vivo situation, it likely, at least in
part, reflects the pathological condition under which acti-
vated microglia can influence the survival of neighboring
neurons in the living brain. Further studies are, however,
required to validate mechanisms underlying the neuro-
protective property of securinine in animalmodels of inflam-
mation-mediated neurodegenerative diseases including PD.
5. Conclusion
In summary, our results demonstrate that the neuroprotective
properties of securinine may be due to inhibition of glial
activation and subsequent generation of proinflammatory
factors. Mechanistically, this appears to involve inhibition of
the p38 MAP kinase-NF-𝜅B pathway resulting in reduced
expression of proinflammatory genes and release of corre-
sponding gene products.
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